Part

Sutro Biopharma Reports Full Year 2023 Financial Results, Business Highlights and Select Anticipated Milestones

Retrieved on: 
Monday, March 25, 2024
CBFA2T3, Endometrial cancer, NSCLC, ASH, AML, International, Part, Patient, SAN, STRO, Acute myeloid leukemia, Cancer, Spacecraft, Lung cancer, RAM, PROC, Investment, Phenotype, Society, ADC, Hematology, Nursing

SOUTH SAN FRANCISCO, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today reported its financial results for the full year 2023, its recent business highlights, and a preview of select anticipated milestones.

Key Points: 
  • “The year 2023 was pivotal for Sutro, with the initiation of REFRαME-O1, our registration-directed study of luvelta for platinum-resistant ovarian cancer (PROC) patients, further validating our next-generation ADC capabilities.
  • The registration-directed trial, REFRαME-O1, for treatment of PROC is enrolling, with an anticipated ~140 sites in ~20 countries to be opened by the end of 2024.
  • Upon exercising the option, Vaxcyte paid Sutro $50 million and is obligated to pay Sutro an additional $25 million within six months.
  • Upon the occurrence of certain regulatory milestones, Vaxcyte would be obligated to pay Sutro up to an additional $60 million.

Willis Lease Finance Corporation Completes Delivery of 4th ATR 72-500 Aircraft under its ConstantThrust® Engine Maintenance Program

Retrieved on: 
Thursday, March 21, 2024
Tax, Pratt & Whitney, Part, ATR, FBO, TAG Airlines, Security (finance), TAG, Aircraft, WLFC, Airline

COCONUT CREEK, Fla., March 21, 2024 (GLOBE NEWSWIRE) -- Willis Lease Finance Corporation (NASDAQ: WLFC) (“WLFC”) announces it has successfully delivered its fourth ATR 72-500 aircraft to Transportes Aéreos Guatemaltecos (TAG Airlines) (“TAG”) as part of its lease agreements with the airline for four ATR 72-500 aircraft.

Key Points: 
  • COCONUT CREEK, Fla., March 21, 2024 (GLOBE NEWSWIRE) -- Willis Lease Finance Corporation (NASDAQ: WLFC) (“WLFC”) announces it has successfully delivered its fourth ATR 72-500 aircraft to Transportes Aéreos Guatemaltecos (TAG Airlines) (“TAG”) as part of its lease agreements with the airline for four ATR 72-500 aircraft.
  • Under the lease agreements, the aircraft are included in WLFC’s ConstantThrust® program for PW127M engines.
  • “We are thrilled to support TAG, our first regional ConstantThrust® airline partner, with a fourth aircraft delivery,” said Austin C. Willis, Chief Executive Officer of WLFC.
  • Willis Lease Finance Corporation (“WLFC”) leases large and regional spare commercial aircraft engines, auxiliary power units and aircraft to airlines, aircraft engine manufacturers and maintenance, repair, and overhaul providers worldwide.

Theratechnologies Initiates Increased Dose Level in Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer

Retrieved on: 
Thursday, March 21, 2024
Toxicity, Associate, FACOG, Part, Wayne State University, Patient, MRC, Rest, Peripheral neuropathy, Senior, TSX, Safety, Gynecologic Oncology (journal), Infrared spectroscopy correlation table, FDA, Food, Pharmaceutical industry

The study’s Medical Review Committee (MRC) has deemed the dose level in the first cohort of patients safe and has approved initiation of the next cohort with an increased dose, in accordance with the updated dose optimization protocol.

Key Points: 
  • The study’s Medical Review Committee (MRC) has deemed the dose level in the first cohort of patients safe and has approved initiation of the next cohort with an increased dose, in accordance with the updated dose optimization protocol.
  • Study centers are now actively recruiting patients for the second cohort, with one patient already enrolled and treated with the higher dose.
  • The dose for the initial six patients was 1.75 mg/kg/dose and the dose for the next cohort of patients is 2.50 mg/kg/dose.
  • Further details about the study design, participation criteria and contact information for the sites can be found at: https://clinicaltrials.gov/study/NCT04706962 .

Mineralys Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, March 21, 2024
Research, American Heart Association, Administration, Conference call, Conference, Target, Obesity, Prevalence, CKD, Part, Patient, SGLT2, G&A, Pivotal, Insurance, Investment, Research and development, AHA, Therapy, EGFR, Senior management, Safety, Chronic kidney disease, Hypertension, Leptin, BMI, Aldosterone, Pharmaceutical industry

RADNOR, Pa., March 21, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone, today announced financial results for the fourth quarter and full year ending December 31, 2023, and provided a corporate update.

Key Points: 
  • R&D expenses for the quarter ended December 31, 2023 were $23.7 million, compared to $7.8 million for the quarter ended December 31, 2022.
  • G&A expenses were $4.0 million for the quarter ended December 31, 2023, compared to $2.2 million for the quarter ended December 31, 2022.
  • Total other income, net was $3.3 million for the quarter ended December 31, 2023, compared to $0.9 million for the quarter ended December 31, 2022.
  • Net loss was $24.4 million for the quarter ended December 31, 2023, compared to $9.1 million for the quarter ended December 31, 2022.

Americas Gold and Silver Corporation Announces Upsize of Private Placement to up to C$7.5 Million

Retrieved on: 
Thursday, March 21, 2024
Indian stock exchange, Offering, Part, Sale, Toronto Stock Exchange, National instrument, American Market, TSX, Gold, USAS, Security (finance)

TORONTO, March 20, 2024 (GLOBE NEWSWIRE) -- Americas Gold and Silver Corporation (TSX: USA, NYSE American: USAS) (the “Company”) is pleased to announce that it has entered into an amending agreement with Eight Capital, as agent, to upsize the previously announced private placement. In connection with the upsized offering, the Company will issue up to 25,000,000 units of the Company (the “Units”) at a price of C$0.30 per Unit (the “Offering”) for aggregate gross proceeds of up to C$7,500,000. In addition, the Company and Eight Capital have agreed that Eight Capital shall be granted an option to sell an additional 1,000,000 Units for additional gross proceeds of up to C$300,000.

Key Points: 
  • TORONTO, March 20, 2024 (GLOBE NEWSWIRE) -- Americas Gold and Silver Corporation (TSX: USA, NYSE American: USAS) (the “Company”) is pleased to announce that it has entered into an amending agreement with Eight Capital, as agent, to upsize the previously announced private placement.
  • In addition, the Company and Eight Capital have agreed that Eight Capital shall be granted an option to sell an additional 1,000,000 Units for additional gross proceeds of up to C$300,000.
  • Each Unit will be comprised of one common share of the Company (each, a “Common Share”) and one common share purchase warrant of the Company (a “Warrant”).
  • Prospective investors should read this offering document before making an investment decision in any LIFE Units.

ElectraMeccanica Vehicles Corp. Reports Results of Special Meeting of Shareholders

Retrieved on: 
Wednesday, March 20, 2024
Proxy, Part, Acquisition, Shareholder, Meeting, Arrangement

MESA, Ariz., March 20, 2024 (GLOBE NEWSWIRE) -- ElectraMeccanica Vehicles Corp. (NASDAQ: SOLO) (“ElectraMeccanica”), a designer and assembler of electric vehicles, today announces the results of the special meeting of shareholders of ElectraMeccanica (the “Shareholders”) held virtually on Wednesday, March 20, 2024 (the “Meeting”), including the adoption of the Arrangement (as defined below) by the Shareholders.

Key Points: 
  • MESA, Ariz., March 20, 2024 (GLOBE NEWSWIRE) -- ElectraMeccanica Vehicles Corp. (NASDAQ: SOLO) (“ElectraMeccanica”), a designer and assembler of electric vehicles, today announces the results of the special meeting of shareholders of ElectraMeccanica (the “Shareholders”) held virtually on Wednesday, March 20, 2024 (the “Meeting”), including the adoption of the Arrangement (as defined below) by the Shareholders.
  • The ElectraMeccanica Arrangement Proposal was required to be approved by the affirmative vote of two-thirds of the votes cast by Shareholders present in person or represented by proxy and entitled to vote at the Meeting.
  • A total of 16,559,479 votes, or approximately 86.2% of the votes cast at the Meeting by Shareholders, were cast in favour of the ElectraMeccanica Arrangement Proposal.
  • Closing of the Arrangement remains subject to certain customary closing conditions, including court approval.

ONWARD® Medical Launches Capital Increase by Way of an Accelerated Bookbuild Offering and of a Public Offering in France for an Indicative Amount of EUR 15 Million, with an Up to EUR 5 Million Upsize Option

Retrieved on: 
Wednesday, March 20, 2024
Failure, Economy, Brussels Stock Exchange, Exercise, Patient, Risk, European, Intellectual property, Marketing, SCI, Annual, Public, Private, KBC, AFM, Prospectus, Royal Victorian Order, VWAP, ARC, Hand, Acceleration, Part, Research, Classification, Enrollment, Certification, DSM-IV codes, CSO, FDA, Movement, Engineering, EUR, Private placement, BCI, Offerings, Public offering, Market, Issue, Euronext Amsterdam, Probability, Security (finance)

The Issue Price will be determined by the accelerated book-building initiated with institutional investors.

Key Points: 
  • The Issue Price will be determined by the accelerated book-building initiated with institutional investors.
  • The Public Offering will not extent to retail investors located outside of France.
  • The New Shares will be issued from the Company’s authorized capital under exclusion of the existing shareholders’ pre-emptive rights.
  • It is the Company’s intention to raise gross proceeds of approximately €15.0 million from the Offerings, with an up to €5 million upsize option.

Americas Gold and Silver Corporation Announces Private Placement of up to C$6.5 Million

Retrieved on: 
Wednesday, March 20, 2024
Offering, Part, Sale, Toronto Stock Exchange, National instrument, American Market, TSX, Gold, Unit, USAS, Security (finance)

TORONTO, March 20, 2024 (GLOBE NEWSWIRE) -- Americas Gold and Silver Corporation (TSX: USA, NYSE American: USAS) (the “Company”) is pleased to announce that it has entered into an agreement with Eight Capital, pursuant to which the Eight Capital has agreed to act as agent, on a “best efforts” basis, in connection with a private placement of up to 21,667,000 units of the Company (the “Units”) at a price of C$0.30 per Unit (the “Issue Price”) for gross proceeds of up to C$6,500,100 (the “Offering”).

Key Points: 
  • Each Unit will be comprised of one common share of the Company (each, a “Common Share”) and one common share purchase warrant of the Company (a “Warrant”).
  • Each Warrant will entitle the holder thereof to purchase one common share of the Company (each, a “Warrant Share”) at an exercise price of C$0.40 per Warrant Share for a period of 36 months following the closing of the Offering.
  • There is an offering document related to the Offering that can be accessed under the Company’s profile at www.sedarplus.ca and on the Company’s website at www.americas-gold.com.
  • Prospective investors should read this offering document before making an investment decision.

Anavex Life Sciences Initiates Placebo-Controlled U.S. Phase 2 Clinical Trial of ANAVEX®3-71 in Schizophrenia

Retrieved on: 
Monday, March 18, 2024
EEG, U.S. FDA, Schizophrenia, Deficit spending, Data analysis, Memory, Alzheimer's disease, Central nervous system, Part, Delusion, Patient, CNS, ERP, Biomarker, Doctor of Philosophy, Parkinson's disease, Quality of life, Personalized medicine, Life, Trial of the century, Positive, Rett syndrome, Hallucination, PANSS, Therapy, SIGMAR1, DSM-IV codes, FDA, Pharmaceutical industry

NEW YORK, March 18, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative, neurodevelopmental, and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, Rett syndrome, schizophrenia, and other central nervous system (CNS) diseases, today announced that the first patient in its U.S. FDA cleared placebo-controlled Phase 2 clinical study of ANAVEX®3-71 for the treatment of schizophrenia has been screened ahead of schedule.

Key Points: 
  • “Initiating our Phase 2 trial of ANAVEX®3-71 in schizophrenia ahead of schedule is a testament to the hard work and dedication of our clinical study team,” stated Christopher U Missling, PhD, President and Chief Executive Officer of Anavex.
  • “Schizophrenia is a challenging disorder that can impair social and occupational functions and overall quality of life for the nearly 24 million people affected worldwide.
  • The placebo-controlled Phase 2, two-part, in-patient trial, ANAVEX®3-71-SZ-001 ( NCT06245213 ), will investigate the effects of ANAVEX®3-71 in patients with schizophrenia.
  • In addition to the electrophysiological biomarkers, Anavex is applying novel neuroinflammatory, metabolomic, and transcriptomic biomarkers at the intersection of schizophrenia pathophysiology and ANAVEX®3-71’s novel, dual mechanism of action.

Baker Hughes’ Emissions Abatement Technology Enables bp to Achieve Flare Emissions Monitoring Breakthrough

Retrieved on: 
Thursday, March 14, 2024
Carbon, Temperature, Pressure, Partnership, Part, Baker Hughes, Flare, Methane, BP, Natural gas

HOUSTON and LONDON, March 14, 2024 (GLOBE NEWSWIRE) --  Baker Hughes (NASDAQ: BKR), an energy technology company, has announced a breakthrough in flare emissions monitoring following a collaboration with bp .

Key Points: 
  • HOUSTON and LONDON, March 14, 2024 (GLOBE NEWSWIRE) --  Baker Hughes (NASDAQ: BKR), an energy technology company, has announced a breakthrough in flare emissions monitoring following a collaboration with bp .
  • Using Baker Hughes’ emissions abatement technology, flare.IQ , bp is quantifying methane emissions from its flares, a new application for the upstream oil and gas sector.
  • With no universally accepted solution to quantifying methane emissions from flares, bp and Baker Hughes conducted one of the largest ever full-scale studies of flare combustion, including testing a range of flares under challenging conditions and verifying the accuracy of flare.IQ technology.
  • Alongside flare.IQ, Baker Hughes has a broad, proven portfolio of emissions abatement technologies capable of improving productivity, efficiency and delivering increased value at scale across customer operations.